FindTrial
Sign In

Immune Responses to BCG Vaccination in Malawi and the UK

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00241657
Enrollment
Unknown
Registered
2005-10-19
Start date
Unknown
Completion date
Unknown
Last updated
2005-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypersensitivity, Delayed Type, Immunity, Cellular

Brief summary

BCG vaccination has been found to provide greater protection against TB in the UK than in Malawi. This study compares immune responses in BCG-vaccinated and unvaccinated teenagers and young adults in Malawi and in the UK.

Interventions

BIOLOGICALBCG

Sponsors

London School of Hygiene and Tropical Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
12 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

* BCG unvaccinated * HIV negative * Not pregnant * Informed Consent

Exclusion criteria

* HIV positive * Pregnant * Seriously ill

Design outcomes

Primary

MeasureTime frame
Delayed-type hypersensitivity—
cytokine responses (eg IFNg) to mycobacterial antigens—

Secondary

MeasureTime frame
scar size—

Countries

Malawi, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026